MyCare - Patients: View your medical records securely online here.
Log in Learn More

Cancer Research

Finding new and better ways to tackle cancer

Changing Medical Practice: The ATAC Trial

Lipson Cancer Center was the lead facility in Rochester contributing to the ATAC trial for post-menopausal women with breast cancer. This trial involved 9,000 women worldwide, and led to the approval of Anastrazole as the currently most potent hormonal medication used to prevent the recurrence of breast cancer.

Every moment of every day, across the globe and here at Rochester General, clinical research is under way to prevent, detect and treat cancer, and to improve the quality of life for cancer patients.

For patients who opt to volunteer, the opportunity to receive an investigational treatment before it’s widely available can bring renewed hope and a greater sense of control over the disease.

At Lipson Cancer Center, clinical research is a top priority, bringing to our community the best investigational treatments from world-class academic centers and pharmaceutical developers. Our partnership with Roswell Park Cancer Institute in Buffalo, for example, benefits the Rochester community by delivering the most promising new cancer drugs, devices and other treatments. All clinical trials follow strict monitoring guidelines to ensure patient safety.

At Roswell Park, Phase I trials test varying dosages of a drug on a small group of patients to ensure the treatment’s safety and effectiveness. Back here in Rochester, the Lipson Cancer Center takes the next steps, carrying out Phase II and III studies. Phase II trials test new treatments in patients with a particular cancer diagnosis, and Phase III trials compare new treatments to older, standard therapies.

Highlights of Cancer Research at Lipson Cancer Center

  • In a series of phase III trials, the Lipson Cancer Center was the first upstate New York cancer center to offer Herceptin to patients with recurrent breast cancer.
  • The Lipson Cancer Center is one of a few sites nationwide that make the promising drug Alimpta available with malignant mesothelioma.

For more information, contact the clinical research nurse at the Lipson Cancer Center, at (585) 922-4020, or visit the National Cancer Institute (NCI) or www.clinicaltrials.gov Web sites.

Search for Cancer Clinical Trials